Show simple item record

dc.contributor.authorDearnaley, D
dc.contributor.authorJovic, G
dc.contributor.authorSyndikus, I
dc.contributor.authorKhoo, V
dc.contributor.authorCowan, Richard A
dc.contributor.authorGraham, J
dc.contributor.authorAird, E
dc.contributor.authorBottomley, D
dc.contributor.authorHuddart, R
dc.contributor.authorJose, C
dc.contributor.authorMatthews, J
dc.contributor.authorMillar, J
dc.contributor.authorMurphy, C
dc.contributor.authorRussell, J M
dc.contributor.authorScrase, C
dc.contributor.authorParmar, M
dc.contributor.authorSydes, M
dc.date.accessioned2014-03-27T10:15:52Z
dc.date.available2014-03-27T10:15:52Z
dc.date.issued2014-02-25
dc.identifier.citationEscalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. 2014: Lancet Oncolen
dc.identifier.issn1474-5488
dc.identifier.pmid24581940
dc.identifier.doi10.1016/S1470-2045(14)70040-3
dc.identifier.urihttp://hdl.handle.net/10541/314875
dc.description.abstractThe aim of this trial was to compare dose-escalated conformal radiotherapy with control-dose conformal radiotherapy in patients with localised prostate cancer. Preliminary findings reported after 5 years of follow-up showed that escalated-dose conformal radiotherapy improved biochemical progression-free survival. Based on the sample size calculation, we planned to analyse overall survival when 190 deaths occurred; this target has now been reached, after a median 10 years of follow-up.
dc.languageENG
dc.language.isoenen
dc.rightsArchived with thanks to The lancet oncologyen
dc.titleEscalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial.en
dc.typeArticleen
dc.contributor.departmentThe Institute of Cancer Research, London, UKen
dc.identifier.journalThe Lancet Oncologyen
dc.description.collectionLymphoma Research Teamen
html.description.abstractThe aim of this trial was to compare dose-escalated conformal radiotherapy with control-dose conformal radiotherapy in patients with localised prostate cancer. Preliminary findings reported after 5 years of follow-up showed that escalated-dose conformal radiotherapy improved biochemical progression-free survival. Based on the sample size calculation, we planned to analyse overall survival when 190 deaths occurred; this target has now been reached, after a median 10 years of follow-up.


Files in this item

This item appears in the following Collection(s)

Show simple item record